Rapport Therapeutics, Inc. RAPP Income Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| —— | —— | ||
| $94.79M+55.6% | $60.94M+118% | ||
| —— | —— | ||
| $125.1M+50.6% | $83.06M+130% | ||
| -$125.1M-50.6% | -$83.06M-130% | ||
| $13.62M+187% | $4.75M— | ||
| -$111.48M-42.4% | -$78.31M-125% | ||
| -$2.85+78.7% | -$13.39+42.0% | ||
| -$124.08M-50.9% | -$82.22M— | ||
| -$125.1M-50.6% | -$83.06M-130% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Rapport Therapeutics, Inc. profitable?
- Rapport Therapeutics, Inc. is not currently profitable: it reported a net loss of $107.3M over the trailing twelve months.
- What is Rapport Therapeutics, Inc.'s earnings per share?
- Rapport Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.59.
- Where does Rapport Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.